Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 14, 2021
CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022 Melbourne, Australia: CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19...
-
Oct 14, 2021
Summit, NJ, USA 14 Oct 2021 Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published...
-
Oct 14, 2021
• Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced...
-
Oct 12, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive committee members Lee Heeson and Gregory Oakes to leave the company for personal reasons Succession planning ongoing St. Gallen, Switzerland,...
-
Oct 8, 2021
CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...
-
Oct 5, 2021CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion.
CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion. 05 Oct 2021 Global biotech leader CSL has...
-
Oct 4, 2021
• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of...
-
Sep 27, 2021
First orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan Partner Kissei to market TAVNEOS® in Japan, with launch expected as soon as...
-
Sep 17, 2021Here's how CSL is working around the world with academia, industry and governments to combat COVID-19
CSL has remained agile to stay ahead of the pandemic challenges and has redirected resources to where it can add the most value to address the pandemic challenges. From the time the coronavirus...
-
Sep 16, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis...
-
Sep 13, 2021
CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...
Sep 11, 2021Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership Development, Workforce Diversity and Job Creation and Training.Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership...
-
Aug 31, 2021
2021 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) includes new recommendations on management of iron deficiency with Ferinject® (ferric carboxymaltose)...
-
Aug 24, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing...
-
Aug 19, 2021
• Appoints Roberta Duncan as new program lead to drive technology advancement • Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza Summit, NJ, USA 19 Aug...
-
Aug 9, 2021The updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients
The updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients 09 Aug 2021 KING OF PRUSSIA, Pa. – Aug. 9, 2021 – Global...
-
Aug 5, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 5.0% and EBITDA up 5.3% at constant exchange rates (CER), as patient access recovered in line with easing COVID-19 restrictions in key...
-
Aug 3, 2021Approval received to co-package a convenience administration kit along with the product BERINERT.
KING OF PRUSSIA, PA 03 Aug 2021 CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for...
-
Jul 27, 2021
The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Summit, NJ, USA 27 Jul 2021 Seqirus offers a...
-
Jun 24, 2021
COVID-19 pandemic significantly impacted the DIAMOND study, leading to lower-than-anticipated enrolment and slower incidence of cardio-vascular events Independent study Executive Committee...
-
Jun 24, 2021
Abbas Hussain will take over as CEO of the Vifor Pharma Group on 16 August 2021 Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons St. Gallen,...
-
Jun 8, 2021Hizentra will be covered under the same Medicare benefit category as intravenous immune globulin (IVIg), but with the convenience of self-infusing at home
KING OF PRUSSIA, Pa. 08 Jun 2021 Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare...
-
Jun 2, 2021CSL continues to provide medicines to patients around the world.
Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. We’re also exploring new...
-
Jun 1, 2021
$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary...
-
Jun 1, 2021
First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Liverpool, UK 01 Jun 2021 Seqirus Liverpool is the...
-
May 16, 2021Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period
KING OF PRUSSIA, Pa. 16 May 2021 Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more...
-
May 13, 2021Dr. Minnie Sarwal of NephroSant has been selected to receive the $25,000 Innovation Award
NEW YORK, NY, USA – May 13, 2021 – Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a...
-
May 12, 2021
New Patent Box policy will benefit domestic commercialisation of medical research Melbourne, Australia: CSL welcomes the Federal Government’s Budget commitment to introduce a Patent Box that...
-
May 12, 2021
Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...
-
May 6, 2021
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors Dividend of CHF 2.00 approved
-
May 6, 2021
Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...
-
May 6, 2021• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.
KING OF PRUSSIA, PA, USA – MAY 6, 2021 – Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) for
-
May 1, 2021
Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...
-
Apr 30, 2021
Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed...
-
Apr 29, 2021
Topline data expected in the second half of 2021 St. Gallen, Switzerland, and Uniondale, NY, 29 April 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of...
-
Apr 29, 2021
Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...
-
Apr 29, 2021The label update is based on open label extension data from the landmark PATH (Polyneuropathy And Treatment with Hizentra) study
KING OF PRUSSIA, Pa. – April 29, 2021 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra®...
-
Apr 28, 2021
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is...
-
Apr 8, 2021
CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and...
Apr 2, 2021CSL continues to provide medicines to patients around the world. Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide...
-
Apr 2, 2021
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 CSL and AstraZeneca have agreed for CSL to manufacture approximately 50...
-
Apr 2, 2021Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19
Osaka, JAPAN and King of Prussia, Pa., USA 02 Apr 2021 The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial...
-
Mar 30, 2021
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the first therapy available in Europe...
-
Mar 26, 2021
St. Gallen, Switzerland, 26 March 2021 – Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6...
-
Mar 24, 2021
Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling. The release follows the completion of...
-
Mar 8, 2021
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVATM injection would be first therapy for treatment of pr uritus in hemodialysis patients...
-
Mar 3, 2021
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 Net sales up 3.7% at constant exchange rates (CER), despite significant...
-
Feb 12, 2021
CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards...
-
Feb 2, 2021
Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board Dr Gianni Zampieriand Gilbert Achermann will not stand for re-election St. Gallen, Switzerland, 02 February 2021
-
Jan 31, 2021
24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin January 31, 2021, Melbourne: CSL Behring Australia, a subsidiary of CSL Limited, today announced that...
-
Jan 25, 2021• TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.
NEW YORK – (January 25, 2021) – Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community...
-
Dec 21, 2020
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from...
-
Dec 14, 2020
This news release is intended for Health Professional media only. Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the...
-
Dec 14, 2020
Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention and influenza pandemic response, today presented new late-breaking data from a systematic review and meta-analysis at...
-
Dec 11, 2020
11 Dec 2020 The University of Queensland (UQ) and CSL today announce that the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine has shown that it elicits a robust response towards the virus and...
-
Dec 9, 2020First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa.– December 9, 2019 – Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...
-
Nov 26, 2020
In its sixth year, a growing international coalition underlines significant harm to health caused by iron deficiency Impact on women moves up political agenda at REYKJAVÍK GLOBAL FORUM - WOMEN...
-
Nov 19, 2020
Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data Veltassa® will benefit from Fresenius Kabi’s...
Nov 19, 2020- Reduction in number of attacks is leading factor when evaluating prophylactic therapyKING OF PRUSSIA, Pa. 19 Nov 2020 CSL Behring, a global biotherapeutics leader, today announced survey results showing that a vast majority of HAE patients (94%) say it’s important their...
-
Nov 16, 2020
16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...
-
Nov 16, 2020- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia
KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa. 16 Nov 2020 Global biotherapeutics leader CSL Behring today announced a community partnership with six Urban League affiliates across the U.S., starting...
-
Nov 13, 2020
Ferinject® significantly reduced the incidence of heart failure hospitalizations in patients with iron deficiency after acute heart failure Results of the AFFIRM-AHF trial support the use of...
-
Nov 10, 2020Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets
KING OF PRUSSIA, Pa. 10 Nov 2020 Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year’s American Heart Association (AHA)...
-
Nov 9, 2020
Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is a first in class small-molecule hepatocyte growth factor (HGF) mimetic, addressing a...
-
Nov 8, 2020
CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne. November 8, 2020, Melbourne — CSL Limited (ASX:CSL) CSL today confirmed it will commence...
-
Nov 5, 2020The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack
KING OF PRUSSIA, Pa. 05 Nov 2020 Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Nov 3, 2020
Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal phase-III ADVOCATE trial of avacopan St...
-
Nov 2, 2020• Both US and European regulators grant special designation
KING OF PRUSSIA, Pa. 02 Nov 2020 Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug designation from...
-
Oct 29, 2020
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list. It...
-
Oct 29, 2020- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
KING OF PRUSSIA, Pa. 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited (parent company of CSL Behring) to its World’s Best Employers 2020 list. It is the fourth year...
-
Oct 20, 2020
Vifor Pharma secures US commercial rights for i.v. Korsuva in non-Fresenius Medical Care dialysis clinics representing approx. 66% of the market, under a profit-sharing arrangement with Cara Cara...
-
Oct 20, 2020• Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential preventative or treatment options in the fight against COVID-19
MELBOURNE, AU and KING OF PRUSSIA, PA 20 Oct 2020 In its annual R&D briefing to investors today, CSL Limited (ASX:CSL; USOTC:CSLLY) demonstrated how the company is advancing a novel research...
-
Oct 15, 2020
Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years, to investigate new ways to fight two of the world’s biggest health...
-
Oct 14, 2020
The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza...
-
Oct 8, 2020
October 8, 2020, Melbourne — CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, Seqirus, has signed a final agreement (Agreement) with the Commonwealth of Australia for the...
-
Oct 8, 2020• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
Osaka, JAPAN and King of Prussia, Pa., USA – October 8,2020 – The CoVIg-19 Plasma Alliance, an unprecedented collaboration of leading plasma companies supported by global organizations outside...
-
Oct 1, 2020
CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office...
-
Sep 28, 2020HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older
KING OF PRUSSIA, PA – September 28, 2020 – CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication...
Sep 24, 2020The study narrowly missed statistical significance on the primary endpoint Pre-specified adjustment of COVID-19 impact, the study showed a statistically significant advantage The totality of...
-
Sep 18, 2020
Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435 In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of...
-
Sep 7, 2020
CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...
-
Sep 4, 2020- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness
MARBURG, Germany 4 September 2020 - CSL Behring a global biotherapeutics leader announced today that the company will host a symposium focused on the challenges of treating lung disease in the...
-
Sep 1, 2020Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
St Gallen, September 1, 2020 – Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1,...
-
Aug 18, 2020
Development of the University of Queensland’s vaccine candidate remains CSL’s priority. However, we are currently in discussions with AstraZeneca and the Australian Government to assess...
-
Aug 6, 2020
Net sales and EBITDA continued to grow in H1 2020 despite challenging market conditions due to COVID-19 Ferinject®/ Injectafer® demand impacted by global COVID-19 restrictions Sustained growth...
-
Jul 30, 2020
Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...
-
Jul 30, 2020
Summit, NJ 30 Jul 2020 Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season Seqirus is...
Jul 30, 2020• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...
-
Jul 18, 2020
The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect. In...
-
Jul 16, 2020
Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care. Less than a third of surveyed healthcare...
-
Jul 13, 2020
Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia The first human trials using the University of Queensland’s (UQ) COVID-19...
-
Jul 9, 2020• Five coagulation researchers named this year’s recipients
KING OF PRUSSIA, Pa. – 9 July 2020 – Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Award for coagulation research just ahead of the...
-
Jul 6, 2020- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
KING OF PRUSSIA, Pa. – 6 July 2020 – Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy...
-
Jun 24, 2020• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
KING OF PRUSSIA, Pa., – 24 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an...
-
Jun 19, 2020
PHILADELPHIA--(June 19, 2020) – The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June 19th: Yi Deng,...
-
Jun 12, 2020Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020
KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever...
-
Jun 8, 2020
This news release is intended for medical, pharmaceutical industry and business media Maidenhead, UK 08 Jun 2020 The European Commission has today given regulatory approval for the first...
-
Jun 8, 2020Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
HATTERSHEIM, Germany – 8 June 2020 – CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...
-
Jun 8, 2020• Builds on CSL Behring’s promise and commitment to the transplant community
KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on...
-
Jun 5, 2020
Oslo, Melbourne and Brisbane 05 Jun 2020 CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate CEPI and CSL will share costs...